906709 - Nektar Therapeutics - SEC Form 4 Insider Trading Screener

Manufactured Goods - Chemicals - Pharmaceutical Preparations - NKTR (906709)
General
Tickers
Insider
Sh Price $
Lqdty M$
Date
Filing Date
  
Trade Date
  
Filing Delay
N Days Ago
Transaction Filing
P - Purchase
S - Sale
A - Grant
D - Sale to Iss
G - Gift
F - Tax
M - Option Ex
X - Option Ex
C - Cnv Deriv
W - Inherited
No deriv Multiple Days
Traded K$
Own Chg %
Industry
Insider Title   Officer
    COB
    CEO
    Pres
    COO
    CFO
    GC
    VP
  Director
  10% Own
  Other
Group by
Sort by
Max Results
Page
clear
Real-time CSV, Options, Alerts
100 results - Yahoo - Google - Finviz - Stockcharts - Tradingview - Stocktwits - SEC
TCcnt1d1w1m6m
S17-1+3+38+0

X

Filing Date

Trade Date

Ticker

Insider Name

Insider Title

Trade Type 

Share Price

Shares Traded

Shares Owned

Own chg

Value Traded

1d ret

1w ret

1m ret

6m ret

D
2017-11-15
NKTRThomsen Jillian B.SVP, Chief Accounting OfficerA - Grant$0.00+15,00060,549+33%+$0
D
2017-11-16
NKTRThomsen Jillian B.SVP, Chief Accounting OfficerD - Sale to issuer$44.23-5,28960,549-8%-$233,932
D
2017-11-15
NKTRRobin Howard WPres, CEOA - Grant$0.00+55,000189,845+41%+$0
D
2017-11-16
NKTRRobin Howard WPres, CEOD - Sale to issuer$44.23-18,069189,845-9%-$799,192
D
2017-11-15
NKTRNicholson JohnSVP, COOA - Grant$0.00+20,000246,536+9%+$0
D
2017-11-16
NKTRNicholson JohnSVP, COOD - Sale to issuer$44.23-6,620246,536-3%-$292,803
D
2017-11-15
NKTRLabrucherie Gil MSVP, CFOA - Grant$0.00+20,00076,716+35%+$0
D
2017-11-16
NKTRLabrucherie Gil MSVP, CFOD - Sale to issuer$44.23-6,69876,716-8%-$296,253
D
2017-11-15
NKTRHora ManinderSVP Pharma Dev, Mfg OpsA - Grant$0.00+15,00067,636+28%+$0
D
2017-11-16
NKTRHora ManinderSVP Pharma Dev, Mfg OpsD - Sale to issuer$44.23-5,59767,636-8%-$247,555
D
2017-11-15
NKTRGergel Ivan P.SVP, Chief Medical OfficerA - Grant$0.00+20,00056,553+55%+$0
D
2017-11-16
NKTRGergel Ivan P.SVP, Chief Medical OfficerD - Sale to issuer$44.23-5,02256,553-8%-$222,123
D
2017-11-15
NKTRDoberstein Stephen KSVP, Chief Scientific OfficerA - Grant$0.00+17,50043,820+66%+$0
D
2017-11-16
NKTRDoberstein Stephen KSVP, Chief Scientific OfficerD - Sale to issuer$44.23-4,78243,820-10%-$211,508
D
2017-11-13
NKTRNicholson JohnSVP, COOM - OptEx$9.24+25,000233,156+12%+$231,000
D
2017-11-13
NKTRNicholson JohnSVP, COOS - Sale+OE$37.78-15,910233,156-6%-$601,080
DM
2017-11-06
NKTRHora ManinderSVP Pharma Dev, Mfg OpsM - OptEx$17.15+39,71758,233+215%+$680,961
D
2017-11-06
NKTRHora ManinderSVP Pharma Dev, Mfg OpsS - Sale+OE$25.07-5,11758,233-8%-$128,283
DM
2017-11-06
NKTRDoberstein Stephen KSVP, Chief Scientific OfficerM - OptEx$9.53+396,32331,102-109%+$3,776,958
DM
2017-11-06
NKTRDoberstein Stephen KSVP, Chief Scientific OfficerS - Sale+OE$29.00-396,32331,102-93%-$11,493,476
D
2017-11-01
NKTRRobin Howard WPres, CEOM - OptEx$11.34+83,334152,914+120%+$945,008
D
2017-11-01
NKTRRobin Howard WPres, CEOS - Sale+OE$23.57-83,334152,914-35%-$1,964,182
D
2017-10-09
NKTRRobin Howard WPres, CEOM - OptEx$11.34+83,333152,914+120%+$944,996
D
2017-10-09
NKTRRobin Howard WPres, CEOS - Sale+OE$24.20-83,333152,914-35%-$2,016,659
D
2017-10-05
NKTRHora ManinderSVP Pharma Dev, Mfg OpsM - OptEx$10.69+7,58358,233+15%+$81,062
D
2017-10-05
NKTRHora ManinderSVP Pharma Dev, Mfg OpsS - Sale+OE$25.00-7,58358,233-12%-$189,575
D
2017-10-05
NKTRDoberstein Stephen KSVP, Chief Scientific OfficerM - OptEx$9.53+43,67731,102-347%+$416,242
D
2017-10-05
NKTRDoberstein Stephen KSVP, Chief Scientific OfficerS - Sale+OE$24.97-43,67731,102-58%-$1,090,615
D
2017-10-02
NKTRLabrucherie Gil MSVP, CFOM - OptEx$11.34+120,00063,414-212%+$1,360,800
D
2017-10-02
NKTRLabrucherie Gil MSVP, CFOS - Sale+OE$24.45-120,00063,414-65%-$2,934,000
DM
2017-09-29
NKTRGergel Ivan P.SVP, Chief Medical OfficerM - OptEx$11.04+100,00041,575-171%+$1,104,000
DM
2017-09-29
NKTRGergel Ivan P.SVP, Chief Medical OfficerS - Sale+OE$24.14-100,00041,575-71%-$2,413,640
2017-09-22
NKTRLingnau LutzDirS - Sale$21.97-5,00027,450-15%-$109,850
2017-09-22
NKTRKuebler Christopher ADirS - Sale$21.86-4,00040,500-9%-$87,440
2017-09-21
NKTRChess RobertDirS - Sale$21.72-6,400274,223-2%-$139,008
D
2017-09-19
NKTRAjer Jeffrey RobertDirA - Grant$0.00+22,50022,500New+$0
D
2017-09-19
NKTRWinger Dennis LDirA - Grant$0.00+9,00048,250+23%+$0
D
2017-09-19
NKTRKuebler Christopher ADirA - Grant$0.00+9,00044,500+25%+$0
D
2017-09-19
NKTRWhitfield Roy ADirA - Grant$0.00+9,000162,000+6%+$0
D
2017-09-19
NKTRLingnau LutzDirA - Grant$0.00+9,00032,450+38%+$0
D
2017-09-19
NKTRKrivulka Joseph JDirA - Grant$0.00+9,00082,000+12%+$0
D
2017-09-19
NKTRGreer R ScottDirA - Grant$0.00+9,000130,333+7%+$0
D
2017-09-19
NKTRChess RobertDirA - Grant$0.00+9,000280,623+3%+$0
D
2017-09-06
NKTRRobin Howard WPres, CEOM - OptEx$11.34+83,333152,914+120%+$944,996
D
2017-09-06
NKTRRobin Howard WPres, CEOS - Sale+OE$21.54-83,333152,914-35%-$1,794,993
2017-08-16
NKTRThomsen Jillian B.SVP, Chief Accounting OfficerS - Sale$19.32-2,64850,838-5%-$51,159
D
2017-08-16
NKTRRobin Howard WPres, CEOM - OptEx$11.34+83,334152,914+120%+$945,008
D
2017-08-16
NKTRRobin Howard WPres, CEOS - Sale+OE$19.26-91,714152,914-37%-$1,766,081
2017-08-16
NKTRNicholson JohnSVP, COOS - Sale$19.32-3,177224,066-1%-$61,380
2017-08-16
NKTRLabrucherie Gil MSVP, CFOS - Sale$19.32-3,17763,414-5%-$61,380
2017-08-16
NKTRHora ManinderSVP Pharma Dev, Mfg OpsS - Sale$19.32-2,95658,233-5%-$57,110
2017-08-16
NKTRGergel Ivan P.SVP, Chief Medical OfficerS - Sale$19.32-1,99741,575-5%-$38,582
2017-08-16
NKTRDoberstein Stephen KSVP, Chief Scientific OfficerS - Sale$19.32-1,70131,102-5%-$32,863
2017-08-10
NKTRWhitfield Roy ADirP - Purchase$17.95+35,000153,000+30%+$628,250
D
2017-07-18
NKTRGergel Ivan P.SVP, Chief Medical OfficerM - OptEx$11.04+54,92043,572-484%+$606,317
D
2017-07-18
NKTRGergel Ivan P.SVP, Chief Medical OfficerS - Sale+OE$21.10-54,92043,572-56%-$1,158,812
D
2017-07-14
NKTRLingnau LutzDirM - OptEx$14.26+30,00023,450-458%+$427,800
D
2017-07-14
NKTRLingnau LutzDirS - Sale+OE$20.76-30,00023,450-56%-$622,800
DM
2017-07-11
NKTRGergel Ivan P.SVP, Chief Medical OfficerM - OptEx$11.04+45,08043,572-2989%+$497,683
DM
2017-07-11
NKTRGergel Ivan P.SVP, Chief Medical OfficerS - Sale+OE$21.08-45,08043,572-51%-$950,318
D
2017-06-26
NKTRKrivulka Joseph JDirM - OptEx$8.37+15,00073,000+26%+$125,550
D
2017-06-07
NKTRNicholson JohnSVP, COOM - OptEx$6.34+150,000227,243+194%+$951,000
D
2017-06-07
NKTRNicholson JohnSVP, COOS - Sale+OE$19.24-101,700227,243-31%-$1,956,708
2017-05-16
NKTRThomsen Jillian B.SVP, Chief Accounting OfficerS - Sale$19.55-2,65152,986-5%-$51,827
2017-05-16
NKTRRobin Howard WPres, CEOS - Sale$19.55-8,388161,294-5%-$163,985
2017-05-16
NKTRNicholson JohnSVP, COOS - Sale$19.55-3,146178,943-2%-$61,504
2017-05-16
NKTRLabrucherie Gil MSVP, CFOS - Sale$19.55-3,17966,091-5%-$62,149
2017-05-16
NKTRHora ManinderSVP Pharma Dev, Mfg OpsS - Sale$19.55-2,95960,689-5%-$57,848
2017-05-16
NKTRGergel Ivan P.SVP, Chief Medical OfficerS - Sale$19.55-1,45043,572-3%-$28,348
2017-05-16
NKTRDoberstein Stephen KSVP, Chief Scientific OfficerS - Sale$19.55-1,70132,803-5%-$33,255
D
2017-05-15
NKTRChess RobertDirM - OptEx$8.37+5,000271,623+2%+$41,850
D
2017-05-15
NKTRChess RobertDirS - Sale+OE$19.79-5,000271,623-2%-$98,950
D
2017-04-17
NKTRChess RobertDirM - OptEx$8.37+5,000271,623+2%+$41,850+3+4
D
2017-04-17
NKTRChess RobertDirS - Sale+OE$18.72-5,000271,623-2%-$93,600+3+4
2017-04-07
NKTRLingnau LutzDirS - Sale$20.05-7,00023,450-23%-$140,350-20+2
D
2017-04-05
NKTRDoberstein Stephen KSVP, Chief Scientific OfficerM - OptEx$9.53+100,00034,504-153%+$953,000-8-7-10
D
2017-04-05
NKTRDoberstein Stephen KSVP, Chief Scientific OfficerS - Sale+OE$21.70-100,00034,504-74%-$2,170,000-8-7-10
D
2017-04-05
NKTRHora ManinderSVP Pharma Dev, Mfg OpsM - OptEx$13.70+180,00063,648-155%+$2,466,000-8-7-10
D
2017-04-05
NKTRHora ManinderSVP Pharma Dev, Mfg OpsS - Sale+OE$21.70-180,00063,648-74%-$3,906,000-8-7-10
D
2017-04-05
NKTRKuebler Christopher ADirM - OptEx$8.37+15,00035,500+73%+$125,550-8-7-10
D
2017-04-05
NKTRKuebler Christopher ADirS - Sale+OE$21.88-15,00035,500-30%-$328,200-8-7-10
D
2017-03-20
NKTRThomsen Jillian B.SVP, Chief Accounting OfficerM - OptEx$9.96+112,50055,637-198%+$1,120,875-2+5-17
D
2017-03-20
NKTRThomsen Jillian B.SVP, Chief Accounting OfficerS - Sale+OE$19.69-112,50055,637-67%-$2,215,125-2+5-17
D
2017-03-15
NKTRWhitfield Roy ADirM - OptEx$8.37+14,000118,000+13%+$117,180+43+45+21
D
2017-03-14
NKTRChess RobertDirM - OptEx$8.37+5,000271,623+2%+$41,850-1+46+19
D
2017-03-14
NKTRChess RobertDirS - Sale+OE$15.41-5,000271,623-2%-$77,050-1+46+19
DM
2017-03-02
NKTRLabrucherie Gil MSVP, CFOM - OptEx$6.70+200,00069,270-153%+$1,340,500-2+5+60
DM
2017-03-02
NKTRLabrucherie Gil MSVP, CFOS - Sale+OE$15.16-200,00069,270-74%-$3,031,950-2+5+60
D
2017-02-21
NKTRLingnau LutzDirM - OptEx$5.14+30,00030,450>999%+$154,200+2-1+71
D
2017-02-21
NKTRLingnau LutzDirS - Sale+OE$13.08-30,00030,450-50%-$392,400+2-1+71
2017-02-16
NKTRThomsen Jillian B.SVP, Chief Accounting OfficerS - Sale$13.14-1,96555,637-3%-$25,820+2+3+69
2017-02-16
NKTRRobin Howard WPres, CEOS - Sale$13.14-8,636169,682-5%-$113,477+2+3+69
2017-02-16
NKTRNicholson JohnSVP, COOS - Sale$13.14-3,237182,089-2%-$42,534+2+3+69
2017-02-16
NKTRLabrucherie Gil MSVP, CFOS - Sale$13.14-2,35969,270-3%-$30,997+2+3+69
2017-02-16
NKTRHora ManinderSVP Pharma Dev, Mfg OpsS - Sale$13.14-2,19563,648-3%-$28,842+2+3+69
2017-02-16
NKTRGergel Ivan P.SVP, Chief Medical OfficerS - Sale$13.14-1,45745,022-3%-$19,145+2+3+69
2017-02-16
NKTRDoberstein Stephen KSVP, Chief Scientific OfficerS - Sale$13.14-1,26134,504-4%-$16,570+2+3+69
D
2017-02-10
NKTRNicholson JohnSVP, COOM - OptEx$4.65+45,000185,326+32%+$209,2500-2+18
D
2017-02-08
NKTRRobin Howard WPres, CEOM - OptEx$4.65+87,500178,318+96%+$406,8750-2+18
D
2017-02-08
NKTRRobin Howard WPres, CEOS - Sale+OE$13.04-87,500178,318-33%-$1,141,0000-2+18

Real-time CSV? Options? Alerts? Contact us!
AAmended filing
DDerivative transaction in filing (usually option exercise)
EError detected in filing
MMultiple transactions in filing; earliest reported transaction date and weighted average transaction price
S - SaleSale of securities on an exchange or to another person
S - Sale+OESale of securities on an exchange or to another person (after option exercise)
F - TaxPayment of exercise price or tax liability using portion of securities received from the company
P - PurchasePurchase of securities on an exchange or from another person
Return to top